Advertisement

French pharma giant Sanofi to begin trials on second Covid vaccine

AFP
AFP - [email protected]
French pharma giant Sanofi to begin trials on second Covid vaccine
This illustration picture taken on November 23, 2020 shows a bottle reading "Vaccine Covid-19" and a seringe next to the Sanofi logo. - The European Commission has signed five contracts to pre-order vaccines, among which with the French-British company Sanofi-GSK (up to 300 million doses). (Photo by JOEL SAGET / AFP)

French pharmaceutical firm Sanofi on Friday announced the launch of human trials of its second Covid-19 vaccine, with its first still in the testing phase after having fallen behind in development.

Advertisement

Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology.

The phase 1 and 2 trials aim to verify that the vaccine is not dangerous and to provide initial information on its effectiveness.

Phase 3 would be carried out on many more patients to determine its effectiveness.

The first trials will include 415 people, with inital results expected in the third quarter.

Advertisement

Messenger RNA technology is also used in the Pfizer/BioNTech and Moderna vaccines, already authorised in the European Union, the United States and elsewhere.

It is the second vaccine developed by Sanofi against the coronavirus.

An earlier candidate, developed with Britain's GSK, is recombinant protein-based, but its development is several months behind schedule and testing is only in phase 2, with hopes to launch it in late 2021.

Sanofi has also agreed to help produce Covid vaccines developed by Pfizer and Johnson & Johnson.

More

Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

See Also